CD28/CCDC9: Protein Involved in Cell-cell Adhesion, Immune Regulation and Disease

Target Name: CCDC9

NCBI ID: G26093

CCDC9

Other Name(s): CCDC9_HUMAN | Coiled-coil domain containing 9 | coiled-coil domain containing 9 | Coiled-coil domain-containing protein 9

CD28/CCDC9: Protein Involved in Cell-cell Adhesion, Immune Regulation and Disease

CCDC9 is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells.

CCDC9 is also known as CD28, and it is a type of protein that is expressed in the T-cells, which are a type of white blood cell that play a key role in the immune system. CCDC9 is involved in the process of cell- cell adhesion, which is the ability of cells to stick together and form tissues.

In addition to its role in cell-cell adhesion, CCDC9 is also involved in the regulation of cell growth and differentiation. It is a positive regulator of the protein kinase PDGFR-尾, which is involved in the process of cell proliferation.

CCDC9 is also involved in the regulation of the immune response. It is a negative regulator of the transfection factor TIM-3, which is involved in the process of immune evasion by cancer cells.

In addition to its role in immune regulation, CCDC9 is also involved in the regulation of the blood-brain barrier. It is a negative regulator of the transmembrane protein brain-derived neurotrophic factor (BDNF), which is involved in the process of neuroprotection and repair.

CCDC9 is also involved in the regulation of the onset of various diseases, including cancer. It is a positive regulator of the tumor suppressor protein p53, which is involved in the process of DNA damage repair and cell apoptosis.

In addition to its role in cancer regulation, CCDC9 is also involved in the regulation of the development and progression of autoimmune diseases. It is a positive regulator of the immune response factor PD-1, which is involved in the regulation of immune tolerance.

CCDC9 is also involved in the regulation of cell death, which is the process by which cells die as a result of various factors, including damage to DNA, UV radiation, and infection with viruses or bacteria. It is a positive regulator of the cell death regulator Bax, which is involved in the process of cell apoptosis.

In addition to its role in cell death regulation, CCDC9 is also involved in the regulation of the regulation of inflammation. It is a positive regulator of the inflammation-promoting protein caspase-12, which is involved in the process of inflammation.

CCDC9 is also involved in the regulation of the regulation of pain perception. It is a positive regulator of the pain perception protein TrkA, which is involved in the process of pain signaling.

In conclusion, CCDC9 is a protein that is involved in a wide range of processes in the body, including cell-cell adhesion, cell growth and differentiation, immune regulation, blood-brain barrier regulation, and disease regulation. As a result, it is a potential drug target and biomarker for a variety of diseases.

Protein Name: Coiled-coil Domain Containing 9

Functions: Probable component of the exon junction complex (EJC), a multiprotein complex that associates immediately upstream of the exon-exon junction on mRNAs and serves as a positional landmark for the intron exon structure of genes and directs post-transcriptional processes in the cytoplasm such as mRNA export, nonsense-mediated mRNA decay (NMD) or translation

The "CCDC9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets